Fol­low­ing se­cre­tive Ab­Cellera pact, Mod­er­na picks up an­oth­er an­ti­body dis­cov­ery deal via Har­bour Bio­Med

As it moves to po­si­tion it­self be­yond pan­dem­ic star­dom, Mod­er­na is spi­der­ing out in­to a num­ber of biotech spheres — work­ing on an Ebo­la vac­cine, look­ing in­to the next it­er­a­tion of can­cer cell ther­a­pies and spend­ing on an an­ti­body dis­cov­ery part­ner­ship.

In its lat­est move, Mod­er­na is adding an­oth­er an­ti­body dis­cov­ery col­lab­o­ra­tion — this time with Har­bour Bio­Med through its new sub­sidiary Nona Bio­sciences, it an­nounced Fri­day. Har­bour sports a plat­form that specif­i­cal­ly de­vel­ops heavy chain-on­ly an­ti­bod­ies, which it says are half the size of tra­di­tion­al an­ti­bod­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER